Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 162 Pages
|多發性骨髓瘤:日本的醫藥品的預測與市場分析 Multiple Myeloma - Japan Drug Forecast and Market Analysis to 2023|
|出版日期: 2015年11月01日||內容資訊: 英文 162 Pages||
本報告提供日本多發性骨髓瘤的治療藥市場相關調查分析，提供您疾病概要和治療指南，競爭情形，主要藥物的詳細資訊 (產品說明，安全性，有效性) 、SWOT分析，銷售額預測，影響分析 (趨勢，推動因素·阻礙因素) 等相關的系統性資訊。
The Multiple Myeloma (MM) market is currently dominated by Velcade and Revlimid, and the market is set to undergo substantial growth between 2013 and 2023. The main drivers of growth will be the launch of monoclonal antibodies (mAbs) Empliciti and daratumumab, which will not only provide a new treatment option for MM patients, but will also lengthen the time between relapses, meaning that the duration of Revlimid and/or Velcade treatments will also be longer. Furthermore, the relatively mild safety profile of these mAbs and the significant efficacies demonstrated by these agents will mean that more MM patients will ultimately receive drug treatment. Label extensions of these mAbs, as well as of second-generation proteasome inhibitors ixazomib and Kyprolis, will further increase treatment options for these patients. The biggest constrainers of the MM market are the increasing cost-consciousness of healthcare providers, as the launch and subsequent label extensions of these pipeline agents will lead to a significant expense, which may impact uptake of these drugs. The patent expiries of Revlimid and Velcade will somewhat alleviate healthcare spending on multiple myeloma patients, which may assist in the uptake of mAbs and second-generation PIs in the multiple myeloma market.
Japan will experience significant market growth, driven by the uptake of the latest premium-priced therapies. KOLs identified the reimbursement of drugs in Japan as a significant barrier to market growth, although oncology drugs are generally reimbursed if they demonstrate clinically significant efficacy.